Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Health Information Services

10X Genomics, Inc. operates as a life science and diagnostics company. The Company develops software for analyzing biological systems such as genetic and immune cells. 10X Genomics serves customers worldwide.
Website: 10xgenomics.com


  • Bad financial results growth rate -1.3% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (11.7%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 1.6% (LTM)
  • Share price is 777.5% higher than minimum and 3.8% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 30.0x)
  • For the last 3 months insiders sold company shares on $6.7 mln (-0.110% of cap.)

Key Financials (Download financials)

Ticker: TXG
Share price, USD:  (0.0%)62.65
year average price 26.14  


year start price 13.93 2025-09-08

min close price 11.34 2025-09-29

max close price 65.12 2026-08-21

current price 62.65 2026-09-07
Common stocks: 113 858 684

Dividend Yield:  0.0%
EV / Sales: 10.4x
Margin (EBITDA LTM / Revenue): -1.6%

Target EV / EBITDA (hist percentile): 30.0x
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 7 133
Net Debt ($m): -458
EV (Enterprise Value): 6 675
EBITDA LTM (млн $): -10
Price to Book: 9.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-22prnewswire.com

10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

2026-01-12prnewswire.com

10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease

2026-01-12prnewswire.com

10x Genomics to Advance Research in Diagnostic Applications of Tumor Single Cell and Spatial Profiling

2025-11-06seekingalpha.com

10x Genomics, Inc. (TXG) Q3 2025 Earnings Call Transcript

2025-09-10seekingalpha.com

10x Genomics, Inc. (TXG) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

2025-08-09seekingalpha.com

10x Genomics, Inc. (TXG) Q2 2025 Earnings Call Transcript

2025-08-07zacks.com

10x Genomics (TXG) Surpasses Q2 Earnings and Revenue Estimates

2025-07-16newsfilecorp.com

Torex Gold Reports Excellent Drilling Results from EPO

2025-06-18newsfilecorp.com

Torex Gold Announces Results of Its 2025 Meeting of Shareholders

2025-06-17newsfilecorp.com

Torex Gold Resources Inc. (TXG) Closes the Market
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-07 2025-08-08 2024-10-29 2024-08-08 2024-04-30 2023-11-03 2023-08-04 2023-05-04 2022-11-03
acceptedDate 2025-11-06 17:36:08 2025-08-07 17:40:53 2025-02-12 18:23:56 2024-10-29 16:10:00 2024-08-08 16:12:32 2024-04-30 16:11:02 2024-02-15 17:16:21 2023-11-02 19:27:55 2023-08-03 18:47:02 2023-05-04 17:04:05 2023-02-16 16:48:47 2022-11-02 20:43:58 2022-02-18 16:06:49 2021-02-26 16:10:27
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 149M 173M 611M 152M 153M 141M 619M 154M 147M 134M 516M 131M 490M 299M
costOfRevenue 49M 48M 196M 45M 46M 45M 209M 58M 47M 36M 120M 30M 74M 58M
grossProfit 100M 125M 414M 106M 107M 96M 409M 96M 100M 98M 396M 101M 416M 240M
grossProfitRatio 0.673 0.723 0.702 0.698 0.678 0.622 0.678 0.733 0.768
researchAndDevelopmentExpenses 57M 61M 265M 66M 63M 68M 270M 108M 71M 67M 266M 67M 212M 123M
generalAndAdministrativeExpenses 0 0 339M 0 0 0 0 0 0 0 295M 0 253M 200M
sellingAndMarketingExpenses 0 0 4M 0 0 0 0 0 0 0 4M 0 5M 2M
sellingGeneralAndAdministrativeExpenses 75M 74M 344M 82M 83M 85M 343M 82M 92M 83M 298M 73M 258M 202M
otherExpenses 0 -41M 0 0 -3M -2M 61M -1M -2M -2M 0 0 0 0
operatingExpenses 133M 95M 609M 148M 149M 155M 675M 190M 163M 150M 564M 141M 469M 326M
costAndExpenses 181M 143M 805M 193M 195M 200M 884M 248M 210M 186M 684M 171M 543M 384M
interestIncome 5M 4M 18M 5M 5M 5M 17M 4M 4M 4M 7M 2M 206 000 2M
interestExpense 3000 3000 4000 2000 1000 1000 33 000 1000 5000 19 000 476 000 114 000 866 000 2M
depreciationAndAmortization 12M 10M 44M 11M 11M 11M 44M 3M 12M 2M 33M 75 000 28M 19M
ebitda -16M 47M -134M -24M -26M -48M -205M -92M -61M -50M -128M -40M -25M -514M
ebitdaratio -0.107 0.27 -0.156 -0.201 -0.34 -0.597 -0.414 -0.37 -0.305
operatingIncome -32M 30M -195M -41M -42M -59M -265M -95M -63M -52M -168M -40M -53M -85M
operatingIncomeRatio -0.216 0.174 -0.274 -0.273 -0.421 -0.617 -0.432 -0.387 -0.305
totalOtherIncomeExpensesNet 4M 7M 17M 7M 5M 2M 17M -1M -2M 2M 6M -39 000 -802 000 -449M
incomeBeforeTax -28M 37M -178M -34M -37M -58M -249M -92M -61M -50M -162M -40M -54M -534M
incomeBeforeTaxRatio -0.189 0.214 -0.227 -0.242 -0.41 -0.597 -0.414 -0.37 -0.305
incomeTaxExpense -733 000 2M 5M 1M 818 000 2M 6M 1M 2M 1M 4M 2M 5M 8M
netIncome -27M 35M -183M -36M -38M -60M -255M -93M -62M -51M -166M -42M -58M -543M
netIncomeRatio -0.184 0.2 -0.236 -0.248 -0.425 -0.605 -0.425 -0.378 -0.32
eps -0.22 0.28 -1.52 -0.3 -0.32 -0.5 -2.18 -0.79 -0.53 -0.44 -1.46 -0.37 -0.53 -5.37
epsdiluted -0.22 0.28 -0.3 -0.32 -0.5 -0.79 -0.53 -0.44 -0.37
weightedAverageShsOut 126M 124M 120M 121M 120M 119M 117M 118M 117M 116M 114M 114M 110M 101M
weightedAverageShsOutDil 126M 125M 120M 121M 120M 119M 117M 118M 117M 116M 114M 114M 110M 101M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-15 2023-02-16 2022-02-18 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 18M 17M 6M -660 000 -150 000
ebit -178M -249M -161M -53M -533M
nonOperatingIncomeExcludingInterest -17M -17M -6M -64 000 447M
netIncomeFromContinuingOperations -183M -255M -166M -58M -543M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -183M -255M -166M -58M -543M
epsDiluted -1.52 -2.18 -1.46 -0.53 -5.37

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-07 2025-08-08 2024-10-29 2024-08-08 2024-04-30 2023-11-03 2023-08-04 2023-05-04 2022-11-03
acceptedDate 2025-11-06 17:36:08 2025-08-07 17:40:53 2025-02-12 18:23:56 2024-10-29 16:10:00 2024-08-08 16:12:32 2024-04-30 16:11:02 2024-02-15 17:16:21 2023-11-02 19:27:55 2023-08-03 18:47:02 2023-05-04 17:04:05 2023-02-16 16:48:47 2022-11-02 20:43:58 2022-02-18 16:06:49 2021-02-26 16:10:27
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 433M 398M 344M 398M 380M 356M 359M 311M 326M 332M 220M 234M 587M 664M
shortTermInvestments 50M 50M 49M 0 269 000 16M 29M 46M 66M 86M 210M 218M 0 0
cashAndShortTermInvestments 482M 447M 393M 398M 380M 372M 389M 357M 391M 418M 430M 452M 587M 664M
netReceivables 97M 119M 88M 84M 91M 91M 115M 104M 88M 78M 104M 84M 85M 51M
inventory 62M 69M 83M 94M 88M 83M 74M 81M 84M 82M 82M 79M 60M 30M
otherCurrentAssets 19M 20M 20M 18M 20M 21M 19M 20M 19M 21M 19M 15M 1M 17M
totalCurrentAssets 660M 656M 584M 594M 579M 567M 596M 562M 583M 602M 635M 629M 748M 774M
propertyPlantEquipmentNet 296M 302M 310M 318M 324M 332M 345M 354M 356M 367M 359M 329M 230M 120M
goodwill 5M 5M 5M 5M 5M 5M 5M 5M 5M 5M 5M 5M 5M 0
intangibleAssets 65M 15M 16M 16M 17M 16M 17M 22M 22M 23M 23M 23M 25M 22M
goodwillAndIntangibleAssets 69M 19M 20M 21M 21M 21M 21M 26M 27M 27M 27M 28M 30M 22M
longTermInvestments 201 000 0 0 0 0 0 0 3M 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 -3M 0 0 0 0 0 0
otherNonCurrentAssets 2M 3M 4M 5M 5M 3M 3M 6M 24M 18M 7M 10M 11M 13M
totalNonCurrentAssets 368M 324M 334M 344M 351M 356M 369M 386M 407M 412M 394M 367M 271M 155M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 1 027M 980M 919M 938M 930M 923M 965M 949M 990M 1 014M 1 029M 996M 1 019M 929M
accountPayables 18M 16M 13M 26M 21M 20M 16M 19M 23M 29M 22M 22M 17M 5M
shortTermDebt 11M 10M 0 19M 22M 11M 0 10M 9M 9M 0 8M 0 0
taxPayables 0 0 5M 4M 6M 6M 5M 4M 2M 2M 4M 3M 5M 9M
deferredRevenue 22M 21M 21M 18M 16M 14M 13M 11M 9M 9M 8M 7M 5M 6M
otherCurrentLiabilities 97M 65M 42M 54M 46M 63M 34M 65M 56M 65M 30M 90M 41M 22M
totalCurrentLiabilities 147M 112M 118M 121M 111M 109M 127M 105M 98M 112M 131M 127M 110M 118M
longTermDebt 76M 77M 0 76M 79M 81M 0 88M 90M 93M 0 88M 0 0
deferredRevenueNonCurrent 11M 11M 13M 12M 11M 10M 9M 0 0 0 3M 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 -10M 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 6M 6M 5M 5M 5M 14M 4M 10M 8M 7M 3M 57M 14M 15M
totalNonCurrentLiabilities 94M 94M 91M 94M 95M 95M 97M 99M 98M 100M 92M 94M 91M 72M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 76M 87M 83M 86M 89M 81M 95M 98M 100M 102M 95M 96M 82M 63M
totalLiabilities 241M 207M 209M 215M 206M 204M 224M 203M 196M 212M 223M 220M 201M 190M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000
retainedEarnings -1 494M -1 467M -1 467M -1 418M -1 382M -1 344M -1 284M -1 235M -1 142M -1 080M -1 029M -1 012M -863M -805M
accumulatedOtherComprehensiveIncomeLoss 138 000 220 000 -493 000 32 000 -430 000 -456 000 -429 000 -677 000 -969 000 -1M -4M -5M 22 000 -50 000
othertotalStockholdersEquity 2 279M 2 240M 2 141M 2 107M 2 064M 1 981M 1 937M 1 884M 1 793M
totalStockholdersEquity 785M 773M 710M 723M 724M 719M 741M 745M 793M 802M 806M 776M 818M 739M
totalEquity 785M 773M 710M 723M 724M 719M 741M 745M 793M 802M 806M 776M 818M 739M
totalLiabilitiesAndStockholdersEquity 1 027M 980M 938M 930M 923M 949M 990M 1 014M 996M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 027M 980M 919M 938M 930M 923M 965M 949M 990M 1 014M 1 029M 996M 1 019M 929M
totalInvestments 50M 50M 49M 0 269 000 16M 29M 46M 66M 86M 210M 218M 0 0
totalDebt 87M 87M 83M 86M 89M 92M 95M 98M 100M 102M 95M 96M 82M 63M
netDebt -346M -311M -261M -312M -290M -264M -264M -213M -226M -230M -125M -138M -505M -601M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-15 2023-02-16 2022-02-18 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 88M 115M 104M 85M 51M
otherReceivables 0 0 0 0 0
prepaids 0 0 0 14M 13M
totalPayables 18M 21M 26M 22M 13M
otherPayables 5M 5M 4M 5M 9M
accruedExpenses 28M 48M 59M 37M 71M
capitalLeaseObligationsCurrent 9M 12M 9M 5M 6M
capitalLeaseObligationsNonCurrent 73M 84M 86M 77M 57M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 2 178M 2 026M 1 839M 1 681M 1 544M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-07 2025-08-08 2024-10-29 2024-08-08 2024-04-30 2023-11-03 2023-08-04 2023-05-04 2022-11-03
acceptedDate 2025-11-06 17:36:08 2025-08-07 17:40:53 2025-02-12 18:23:56 2024-10-29 16:10:00 2024-08-08 16:12:32 2024-04-30 16:11:02 2024-02-15 17:16:21 2023-11-02 19:27:55 2023-08-03 18:47:02 2023-05-04 17:04:05 2023-02-16 16:48:47 2022-11-02 20:43:58 2022-02-18 16:06:49 2021-02-26 16:10:27
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -27M 35M -183M -36M -38M -60M -255M -93M -62M -51M -166M -42M -58M -543M
depreciationAndAmortization 12M 10M 44M 11M 11M 11M 44M 11M 12M 9M 33M 8M 28M 19M
deferredIncomeTax 0 0 0 0 0 0 0 -27M 3M 0 0 0 0 2M
stockBasedCompensation 25M 28M 141M 34M 38M 36M 167M 40M 46M 42M 137M 34M 96M 49M
changeInWorkingCapital 32M -54M 1M 13M -4M -6M 17M 16M -10M -6M -39M -10M -87M -50M
accountsReceivables 7M -66M 27M 8M 122 000 24M -11M -16M -10M 26M -19M -7M -34M -18M
inventory 7M 7M -10M -4M -5M -10M 8M 3M -2M -449 000 -21M -9M -30M -15M
accountsPayables 0 6M -3M 4M 1M 5M -6M -4M 2M -781 000 6M -4M 11M -8M
otherWorkingCapital 18M -858 000 -13M 5M -112 000 -24M 26M 34M -413 000 -31M -5M 10M -34M -10M
otherNonCashItems 1M -351 000 4M 64 000 64M 44M 12M 26M 463 000 2M 2M 660 000 79 000 306M
netCashProvidedByOperatingActivities 43M 18M 7M 22M 7M -16M -15M -25M -12M -4M -34M -10M -21M -218M
investmentsInPropertyPlantAndEquipment -687 000 -2M -12M -4M -4M -3M -49M -15M -25M -5M -132M -37M -101M -38M
acquisitionsNet -9M 0 0 0 0 0 0 0 0 0 -4M -2M -5M 0
purchasesOfInvestments 0 0 -49M 0 0 0 0 0 0 0 -283M -11M 0 0
salesMaturitiesOfInvestments 0 50M 30M 271 000 16M 14M 183M 20M 21M 125M 68M 17M 0 0
otherInvestingActivites 502 000 -49M 0 -1 000 000 14M 20M 0 0 0
netCashUsedForInvestingActivites -9M -939 000 -4M 12M 11M 5M -4M 120M -33M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 0 0 -6M 5M 2M 4M 0 2M 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 617 000 4M 156 000 5M 2M 4M 0 -6M 2M
netCashUsedProvidedByFinancingActivities 617 000 4M 156 000 5M 2M 4M 7M -3M 2M
effectOfForexChangesOnCash -33 000 360 000 -164 000 156 000 -3000 -48 000 -33 000 -85 000 -49 000 24 000 -44 000 -85 000 234 000 -463 000
netChangeInCash 35M 21M -15M 18M 24M -4M 132M -16M -9M 112M -369M -40M -93M 212M
cashAtEndOfPeriod 433M 398M 344M 398M 380M 356M 359M 312M 331M 340M 227M 242M 596M 689M
cashAtBeginningOfPeriod 398M 377M 359M 380M 356M 359M 227M 327M 340M 227M 596M 282M 689M 476M
operatingCashFlow 43M 18M 7M 22M 7M -16M -15M -25M -12M -4M -34M -10M -21M -218M
capitalExpenditure -687 000 -2M -12M -4M -4M -3M -50M -15M -25M -5M -132M -37M -101M -38M
freeCashFlow 43M 16M -6M 18M 4M -19M -65M -41M -37M -9M -165M -46M -123M -256M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-15 2023-02-16 2022-02-18 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -1 000 000 -923 000 0 0 0
netCashProvidedByInvestingActivities -33M 133M -351M -107M -38M
netDebtIssuance 0 -6M -5M -5M -37M
longTermNetDebtIssuance 0 -6M -5M -5M -31M
shortTermNetDebtIssuance 0 0 0 0 -6M
netStockIssuance 11M 19M 21M 40M 482M
netCommonStockIssuance 11M 19M 21M 40M 482M
commonStockIssuance 11M 19M 21M 40M 482M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 0 0 0 0 24M
netCashProvidedByFinancingActivities 11M 14M 16M 35M 469M
incomeTaxesPaid 6M 5M 4M 9M 280 000
interestPaid 0 436 000 841 000 1M 2M

Earning call transcript

2025 q3
2025-11-06 ET (fiscal 2025 q3)
2025 q2
2025-08-09 ET (fiscal 2025 q2)
2025 q1
2025-05-08 ET (fiscal 2025 q1)
2024 q4
2025-02-12 ET (fiscal 2024 q4)
2024 q3
2024-10-29 ET (fiscal 2024 q3)
2024 q2
2024-08-08 ET (fiscal 2024 q2)
2024 q1
2024-04-30 ET (fiscal 2024 q1)
2023 q4
2024-02-15 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-03 ET (fiscal 2023 q1)
2022 q4
2023-02-15 ET (fiscal 2022 q4)
2022 q3
2022-11-02 ET (fiscal 2022 q3)
2022 q2
2022-08-08 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-08-06 ET
10x Genomics Reports Second Quarter 2026 Financial Results
2026-07-29 ET
10x Genomics and Lausanne University Hospital Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies for Cancer Care
2026-07-15 ET
10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026
2026-06-17 ET
10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer
2026-06-09 ET
10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group
2026-05-07 20:05 ET
10x Genomics Reports First Quarter 2026 Financial Results
2026-04-29 20:05 ET
10x Genomics to Participate in the BofA Securities 2026 Healthcare Conference
2026-04-29 13:00 ET
The Quiet Rule Change Tilting $10B Toward Medtech's Most Validated Platforms
2026-04-18 ET
10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and Understood
2026-04-15 ET
10x Genomics to Report First Quarter 2026 Financial Results on May 7, 2026
2026-03-25 ET
Bioptimus Announces STELA: The World's Largest Clinically Linked Spatial Biology Atlas, alongside key partners 10x Genomics and Broad Clinical Labs
2026-03-17 ET
PerturbAI Launches from Stealth, Unveils the World's Largest In Vivo CRISPR Atlas
2026-02-19 21:05 ET
10x Genomics to Participate in the 46th Annual TD Cowen Health Care Conference
2026-02-12 21:05 ET
10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026
2026-02-04 14:00 ET
PharosAI and 10x Genomics Partner to Transform Cancer Research with AI and Spatial Biology
2026-01-22 ET
10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
2026-01-12 ET
10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease
2026-01-12 ET
10x Genomics to Advance Research in Diagnostic Applications of Tumor Single Cell and Spatial Profiling
2026-01-12 ET
Cancer Research Institute Launches Transformative AI-Driven Immuno-Oncology Initiative Powered by 10x Genomics Technology
2026-01-11 ET
10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results
2026-01-07 ET
CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response
2025-12-29 ET
10x Genomics to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-11-18 ET
New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' Xenium
2025-11-11 ET
10x Genomics to Participate in the Wolfe Research Healthcare Conference 2025
2025-11-06 ET
10x Genomics Reports Third Quarter 2025 Financial Results
2025-10-29 ET
10x Genomics Launches the Next Generation of Chromium Flex to Empower Scientists to Massively Scale Single Cell Research
2025-10-20 ET
10x Genomics and Anthropic Partner to Make Single Cell and Spatial Analysis More Accessible Through Claude for Life Sciences
2025-10-09 ET
10x Genomics to Report Third Quarter 2025 Financial Results on November 6, 2025
2025-09-09 ET
CLISEQ, 10X Genomics and Weizmann Institute to Investigate Single Cell Applications in Hematology Clinical Diagnostics
2025-08-27 ET
10x Genomics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
2025-08-19 ET
10x Genomics Launches Xenium Protein, Advancing Spatial Biology by Enabling Same-Cell RNA and Protein Analysis
2025-08-07 ET
10x Genomics Reports Second Quarter 2025 Financial Results
2025-08-07 ET
10x Genomics to Acquire Scale Biosciences
2025-07-17 ET
10x Genomics and A*STAR Genome Institute of Singapore Launch TISHUMAP Study to Advance AI-Driven Drug Target Discovery
2025-07-10 ET
10x Genomics to Report Second Quarter 2025 Financial Results on August 7, 2025
2025-05-14 ET
10x Genomics Announces Patent Litigation Settlement Agreement with Bruker
2025-05-08 ET
10x Genomics Reports First Quarter 2025 Financial Results
2025-04-30 ET
10x Genomics to Participate in the BofA Securities 2025 Healthcare Conference
2025-04-14 ET
10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025
2025-03-03 ET
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products
2025-02-23 ET
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis
2025-02-18 ET
10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference
2025-02-12 ET
10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025
2025-02-06 ET
Chan Zuckerberg Initiative Launches Billion Cells Project with 10x Genomics and Ultima Genomics to Advance AI in Biology
2025-01-28 ET
10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025
2025-01-12 ET
10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2024 Results
2025-01-02 ET
10x Genomics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
2024-11-07 ET
10x Genomics to Present at the Wolfe Research 2024 Healthcare Conference
2024-10-31 ET
TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative
2024-10-29 20:05 ET
10x Genomics Reports Third Quarter 2024 Financial Results
2024-10-15 20:05 ET
10x Genomics Delivers 'Single Cell for a Single Cent' with New Chromium Launches
2024-10-09 20:05 ET
10x Genomics Announces Preliminary Select Third Quarter 2024 Results
2024-10-01 20:05 ET
10x Genomics Announces Mega-Scale Single Cell Analysis for One Cent Per Cell at Human Cell Atlas General Meeting
2024-09-10 13:00 ET
Lausanne Researchers Combine 10x Genomics' Chromium and Xenium for Novel Insights into Resistance and Potential Therapeutics for Brain Cancer
2024-09-03 20:05 ET
10x Genomics Unveils Chromium Xo: A Low-Cost Instrument to Expand Access to High-Performance Single Cell Research
2024-08-22 20:05 ET
10x Genomics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
2024-08-08 20:05 ET
10x Genomics Announces Senior Leadership Changes
2024-08-08 20:04 ET
10x Genomics Reports Second Quarter 2024 Financial Results
2024-08-05 20:00 ET
10x Genomics Technology Supports TenK10K Project Led by Garvan Institute of Medical Research to Help Transform the Treatment of Complex Diseases
2024-07-12 12:00 ET
10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024
2024-06-27 13:00 ET
New Insights Into Cleft Palate Unlocked With 10x Genomics' Single Cell and Spatial Technologies
2024-06-20 13:00 ET
10x Genomics Begins Commercial Shipments of Xenium Prime 5K Pan-Tissue and Pathways Panel
2024-05-29 20:05 ET
10x Genomics Launches 5,000-Plex Gene Panel for Xenium
2024-05-02 20:05 ET
10x Genomics to Present at the BofA Securities 2024 Healthcare Conference
2024-05-01 05:01 ET
Curio Bioscience Reports Clarifying Decision From European Unified Patent Court (UPC)
2024-04-30 20:05 ET
10x Genomics Reports First Quarter 2024 Financial Results
2024-04-10 20:05 ET
10x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024
2024-03-26 13:00 ET
10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay
2024-03-21 20:05 ET
10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel
2024-03-13 20:05 ET
10x Genomics Begins Commercial Shipments of Chromium GEM-X Products
2024-02-20 21:05 ET
10x Genomics to Present at the 44th Annual TD Cowen Health Care Conference
2024-02-15 21:05 ET
10x Genomics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Outlook for 2024
2024-02-07 21:05 ET
10x Genomics Expands Leadership in Single Cell Analysis with Launch of GEM-X Technology
2024-02-05 21:05 ET
10x Genomics to Showcase New Cutting-Edge Technologies and Highlight Innovation Roadmap at 2024 AGBT General Meeting
2024-01-24 21:05 ET
10x Genomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024
2024-01-08 14:00 ET
10x Genomics Announces Preliminary Fourth Quarter and Full Year 2023 Results
2023-12-21 21:05 ET
10x Genomics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-20 21:05 ET
10x Genomics Launches Xenium Catalyst Network
2023-12-19 14:00 ET
Integrative Study Conducted by 10x Genomics Combines Single Cell, Spatial and In Situ Analyses to Investigate Tumor Invasiveness
2023-12-13 21:26 ET
High Sensitivity and Specificity of the Xenium Platform from 10x Genomics Outperforms NanoString's CosMx and Vizgen's Merscope in Benchmarking Preprint
2023-12-07 14:00 ET
10x Genomics and NIH CARD to Create Comprehensive Single Cell Atlas of the Human Brain
2023-11-06 21:05 ET
OWKIN Integrates 10x Genomics Spatial Omics and Single-Cell Technologies to the MOSAIC Study
2023-11-02 20:05 ET
10x Genomics Reports Third Quarter 2023 Financial Results
2023-11-01 20:05 ET
10x Genomics to Present at the Stephens 25th Annual Conference
2023-10-26 20:05 ET
Study Fueled by Xenium Analysis Sheds Light on Resistance Mechanisms in Model of Lethal Pediatric Brain Tumors
2023-10-11 20:05 ET
10x Genomics to Report Third Quarter 2023 Financial Results on November 2, 2023
2023-09-14 20:36 ET
10x Genomics Expands Gene Expression Flex Offering with New High-Throughput Multiomic Profiling Kit
2023-09-05 13:00 ET
Study Enabled by 10x Genomics Single Cell and Spatial Technologies Explains Why Immunotherapy is More Effective for Certain Brain Tumors Than Others
2023-08-30 20:05 ET
10x Genomics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-29 20:30 ET
10x Genomics Surpasses 100 Xenium Analyzer Shipments
2023-08-03 20:05 ET
10x Genomics Reports Second Quarter 2023 Financial Results
2023-07-13 20:05 ET
10x Genomics to Report Second Quarter 2023 Financial Results on August 3, 2023
2023-07-05 23:30 ET
CAR T-Cell Study Enabled by 10x Genomics Single Cell Technology Published in Nature Medicine
2023-05-24 20:05 ET
10x Genomics Launches Visium CytAssist Gene and Protein Expression Assay
2023-05-03 20:05 ET
10x Genomics Reports First Quarter 2023 Financial Results
2023-04-25 20:06 ET
10x Genomics to Present at the BofA Securities 2023 Healthcare Conference
2023-04-12 20:05 ET
10x Genomics to Report First Quarter 2023 Financial Results on May 3, 2023
2023-02-22 21:30 ET
10x Genomics to Present at the 43rd Annual Cowen Healthcare Conference
2023-02-15 21:05 ET
10x Genomics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Outlook for 2023
2023-02-06 14:00 ET
10x Genomics Demonstrates Breadth, Scale and Leadership at 2023 AGBT General Meeting
2023-01-19 21:05 ET
10x Genomics to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023
2022-12-28 21:05 ET
10x Genomics to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-08 21:05 ET
10x Genomics Commercially Launches Xenium Platform for In Situ Analysis
2022-11-09 21:05 ET
10x Genomics Launches BEAM to Improve and Streamline Antibody and T-Cell Receptor Discovery
2022-11-02 20:05 ET
10x Genomics Reports Third Quarter 2022 Financial Results
2022-10-31 20:05 ET
10x Genomics to Host Investor Day on December 8, 2022
2022-10-12 20:05 ET
10x Genomics to Report Third Quarter Financial Results on November 2, 2022
2022-09-02 20:05 ET
10x Genomics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
2022-08-08 20:05 ET
10x Genomics Reports Second Quarter 2022 Financial Results
2022-07-28 20:05 ET
10x Genomics to Present at the UBS Genomics 2.0 and MedTech Innovations Summit
2022-07-14 20:06 ET
10x Genomics Names Jim Wilbur as Chief Commercial Officer
2022-07-14 20:05 ET
10x Genomics Announces Preliminary Second Quarter 2022 Revenue
2022-06-07 11:00 ET
10x Genomics Advances Leadership and Innovation in Single Cell and Spatial Technologies at 2022 AGBT General Meeting
2022-05-04 20:05 ET
10x Genomics Reports First Quarter 2022 Financial Results
2022-04-26 20:05 ET
10x Genomics to Present at the BofA Securities 2022 Healthcare Conference
2022-04-14 12:55 ET
10x Genomics Launches Two New Products to Unlock Wider Range of Samples for Single Cell Analysis on Chromium
2022-04-07 20:05 ET
10x Genomics to Report First Quarter Financial Results on May 4, 2022
2022-03-01 21:05 ET
10x Genomics to Present at the Cowen 42nd Annual Health Care Conference
2022-02-22 21:15 ET
10x Genomics Showcases Robust Innovation Pipeline at Xperience 2022 Event
2022-02-16 21:05 ET
10x Genomics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Outlook for 2022
2022-01-26 21:05 ET
10x Genomics to Report Fourth Quarter and Full Year 2021 Financial Results on February 16, 2022
2022-01-21 14:00 ET
10x Genomics Adds Global Clinical Research Organizations to Expanded Certified Service Provider Network
2021-12-22 21:05 ET
10x Genomics to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-01 22:06 ET
10x Genomics Recognized on The Scientist's Top 10 Innovations List for Fifth Consecutive Year
2021-11-03 20:05 ET
10x Genomics Reports Third Quarter 2021 Financial Results
2021-10-25 10:00 ET
10x Genomics Celebrates Opening of Singapore Manufacturing and Commercial Hub
2021-10-07 20:05 ET
10x Genomics to Report Third Quarter Financial Results on November 3, 2021
2021-08-31 20:05 ET
10x Genomics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
2021-08-06 12:00 ET
10x Genomics to Present at the UBS Genomics 2.0 and MedTech Innovations Summit
2021-08-04 20:05 ET
10x Genomics Reports Second Quarter 2021 Financial Results
2021-07-14 12:00 ET
10x Genomics Introduces New Chromium X Series for Single Cell Analysis
2021-07-07 20:03 ET
10x Genomics to Report Second Quarter Financial Results on August 4, 2021
2021-06-28 07:30 ET
Genuity Science Awarded Designation as a 10x Genomics Certified Service Provider in Single Cell Immune Profiling

SEC forms

Show financial reports only

SEC form 10
2026-08-06 21:31 ET
10X Genomics published news for 2026 q2
SEC form 8
2026-08-06 20:03 ET
10X Genomics published news for 2026 q2
SEC form 8
2026-08-06 20:03 ET
10X Genomics published news for 2026 q2
SEC form 8
2026-05-07 20:03 ET
10X Genomics published news for 2026 q1
SEC form 8
2026-05-07 20:03 ET
10X Genomics published news for 2026 q1
SEC form 10
2026-05-07 17:36 ET
10X Genomics published news for 2026 q1
SEC form 8
2026-02-12 16:09 ET
10X Genomics published news for 2025 q4
SEC form 8
2026-02-12 16:09 ET
10X Genomics reported for 2025 q4
SEC form 8
2025-11-06 21:08 ET
10X Genomics published news for 2025 q3
SEC form 8
2025-11-06 21:08 ET
10X Genomics reported for 2025 q3
SEC form 10
2025-08-07 21:40 ET
10X Genomics reported for 2025 q2
SEC form 8
2025-08-07 20:10 ET
10X Genomics published news for 2025 q2
SEC form 8
2025-08-07 20:10 ET
10X Genomics reported for 2025 q2
SEC form 10
2025-05-09 00:00 ET
10X Genomics published news for 2025 q1
SEC form 10
2025-05-08 21:35 ET
10X Genomics published news for 2025 q1
SEC form 8
2025-05-08 20:05 ET
10X Genomics published news for 2025 q1
SEC form 8
2025-05-08 20:05 ET
10X Genomics reported for 2025 q1
SEC form 10
2025-02-13 00:00 ET
10X Genomics published news for 2024 q4
SEC form 10
2025-02-12 23:23 ET
10X Genomics published news for 2024 q4
SEC form 8
2025-02-12 16:10 ET
10X Genomics published news for 2024 q4
SEC form 8
2025-02-12 16:10 ET
10X Genomics reported for 2024 q4
SEC form 8
2025-01-13 00:00 ET
10X Genomics published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
10X Genomics published news for 2024 q4
SEC form 10
2024-10-29 16:10 ET
10X Genomics reported for 2024 q3
SEC form 10
2024-10-29 00:00 ET
10X Genomics reported for 2024 q3
SEC form 8
2024-10-29 00:00 ET
10X Genomics published news for 2024 q3
SEC form 8
2024-10-29 00:00 ET
10X Genomics reported for 2024 q3
SEC form 8
2024-10-09 00:00 ET
10X Genomics published news for 2024 q3
SEC form 8
2024-10-09 00:00 ET
10X Genomics published news for 2024 q3
SEC form 10
2024-08-08 16:12 ET
10X Genomics reported for 2024 q2
SEC form 8
2024-08-08 16:08 ET
10X Genomics published news for 2024 q2
SEC form 8
2024-08-08 16:08 ET
10X Genomics reported for 2024 q2
SEC form 8
2024-08-08 16:08 ET
10X Genomics published news for 2024 q2
SEC form 10
2024-08-08 00:00 ET
10X Genomics reported for 2024 q2
SEC form 10
2024-04-30 16:11 ET
10X Genomics published news for 2024 q1
SEC form 8
2024-04-30 16:06 ET
10X Genomics published news for 2024 q1
SEC form 8
2024-04-30 16:06 ET
10X Genomics reported for 2024 q1
SEC form 10
2024-04-30 00:00 ET
10X Genomics published news for 2024 q1
SEC form 10
2024-02-15 00:00 ET
10X Genomics published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
10X Genomics published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
10X Genomics reported for 2023 q4
SEC form 8
2024-01-08 00:00 ET
10X Genomics published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
10X Genomics published news for 2023 q4
SEC form 10
2023-11-03 00:00 ET
10X Genomics published news for 2023 q3
SEC form 10
2023-11-02 19:27 ET
10X Genomics published news for 2023 q3
SEC form 8
2023-11-02 16:05 ET
10X Genomics reported for 2023 q3
SEC form 10
2023-08-04 00:00 ET
10X Genomics published news for 2023 q2
SEC form 10
2023-08-03 18:47 ET
10X Genomics published news for 2023 q2
SEC form 6
2023-08-03 16:05 ET
10X Genomics reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
10X Genomics published news for 2023 q2
SEC form 6
2023-07-20 16:05 ET
10X Genomics published news for 2023 q2
SEC form 6
2023-06-16 16:51 ET
10X Genomics published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
10X Genomics published news for 2023 q1
SEC form 8
2023-05-03 00:00 ET
10X Genomics published news for 2023 q1
SEC form 10
2023-02-16 16:48 ET
10X Genomics reported for 2022 q4
SEC form 10
2023-02-16 00:00 ET
10X Genomics reported for 2022 q4
SEC form 6
2023-02-15 16:05 ET
10X Genomics published news for 2022 q4
SEC form 8
2023-02-15 00:00 ET
10X Genomics reported for 2022 q4
SEC form 10
2022-11-03 00:00 ET
10X Genomics reported for 2022 q3
SEC form 10
2022-11-02 20:43 ET
10X Genomics reported for 2022 q3
SEC form 6
2022-11-02 16:05 ET
10X Genomics published news for 2022 q3
SEC form 8
2022-11-02 00:00 ET
10X Genomics reported for 2022 q3
SEC form 10
2022-08-09 00:00 ET
10X Genomics reported for 2022 q2
SEC form 10
2022-08-08 19:30 ET
10X Genomics reported for 2022 q2
SEC form 6
2022-08-08 16:06 ET
10X Genomics published news for 2022 q2
SEC form 8
2022-08-08 00:00 ET
10X Genomics reported for 2022 q2
SEC form 6
2022-08-03 18:59 ET
10X Genomics published news for 2022 q2
SEC form 6
2022-08-03 17:09 ET
10X Genomics published news for 2022 q2
SEC form 6
2022-07-14 16:05 ET
10X Genomics published news for 2022 q2
SEC form 8
2022-07-14 00:00 ET
10X Genomics published news for 2022 q2
SEC form 6
2022-06-17 16:05 ET
10X Genomics published news for 2022 q1
SEC form 10
2022-05-05 16:06 ET
10X Genomics reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
10X Genomics reported for 2022 q1
SEC form 6
2022-05-04 16:06 ET
10X Genomics published news for 2022 q1
SEC form 8
2022-05-04 00:00 ET
10X Genomics reported for 2022 q1
SEC form 6
2022-04-29 16:07 ET
10X Genomics published news for 2022 q1
SEC form 10
2022-02-18 16:06 ET
10X Genomics published news for 2021 q4
SEC form 10
2022-02-18 00:00 ET
10X Genomics published news for 2021 q4
SEC form 6
2022-02-16 16:05 ET
10X Genomics published news for 2021 q4
SEC form 8
2022-02-16 00:00 ET
10X Genomics published news for 2021 q4
SEC form 10
2021-11-05 16:06 ET
10X Genomics published news for 2021 q3
SEC form 10
2021-11-05 00:00 ET
10X Genomics published news for 2021 q3
SEC form 6
2021-11-03 16:05 ET
10X Genomics published news for 2021 q3
SEC form 8
2021-11-03 00:00 ET
10X Genomics published news for 2021 q3
SEC form 10
2021-08-06 16:05 ET
10X Genomics published news for 2021 q2
SEC form 10
2021-08-06 00:00 ET
10X Genomics published news for 2021 q2
SEC form 6
2021-08-04 16:01 ET
10X Genomics published news for 2021 q2
SEC form 8
2021-08-04 00:00 ET
10X Genomics published news for 2021 q2
SEC form 6
2021-07-27 06:05 ET
10X Genomics published news for 2021 q2
SEC form 6
2021-06-15 17:01 ET
10X Genomics published news for 2021 q1
SEC form 6
2021-06-01 18:47 ET
10X Genomics published news for 2021 q1
SEC form 10
2021-05-07 16:07 ET
10X Genomics published news for 2021 q1
SEC form 10
2021-05-07 00:00 ET
10X Genomics published news for 2021 q1
SEC form 6
2021-05-05 16:07 ET
10X Genomics published news for 2021 q1
SEC form 8
2021-05-05 00:00 ET
10X Genomics published news for 2021 q1
SEC form 6
2021-04-23 16:10 ET
10X Genomics published news for 2021 q1
SEC form 6
2021-04-23 16:07 ET
10X Genomics published news for 2021 q1
SEC form 10
2021-02-26 16:10 ET
10X Genomics published news for 2020 q4
SEC form 6
2021-02-17 16:06 ET
10X Genomics published news for 2020 q4
SEC form 10
2020-11-12 16:15 ET
10X Genomics published news for 2020 q3
SEC form 6
2020-11-10 16:05 ET
10X Genomics published news for 2020 q3
SEC form 6
2020-10-13 09:21 ET
10X Genomics published news for 2020 q3
SEC form 6
2020-10-05 16:17 ET
10X Genomics published news for 2020 q3